Improving fundamentals and stabilizing technical baseline. Base building process active. Valuations remain conservative and supported by current metrics.
SENTINEL REVIEW
Expleo Solutions (EXPLEOSOL)•Updated yesterday
🚨 Structural Deterioration Signature: In Q2 FY2027, Expleo Solutions reported a 2.4% YoY revenue growth to ₹302.6 Cr, but net profit contracted by 8.5% to ₹36.4 Cr, with EBITDA margins compressing by 3.4 pp to 16.7%. This deterioration persists across interim quarters since FY2026, with Q1 FY2027 showing 12.0% revenue growth and Q2 FY2027 confirming a 2.4% YoY revenue expansion, though net profit remained under sector median performance. The operational strain is compounded by elevated governance risks, with two board-level resignations in Q2 FY2027, and a cash conversion deficit, though operating cash flow (₹119.5 Cr) has normalized. The company’s zero-debt profile and working capital (trade receivables: ₹229.6 Cr) provide liquidity capacity, but relative growth weakness and governance integrity shocks push the firm into Flagium’s heightened surveillance range.
- ✗Risk score deteriorated (QoQ change: +18 pts)
- ✓Profitability margins pressure eased
- ✗New risk trigger: Relative Growth Weakness (+10.6 pts)
- ✓Growth expectations are conservative
- ✓Market structure is neutral/stabilizing
- ✗A/D flow regime is Neutral (-0.11σ)
- ✗Share price is down -9.9% this quarter (from ₹857.85 on 30 Sept to ₹772.7)
- 🔴Review 2 active forensic warning flags for structural stress
- 🟠Track earnings quality and working capital trends in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 20.1 ptsGovernance
- 13.9 ptsCompetitive Position
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | -8.94% | -3.1% | -5.84% |
| 1 Month | -11.75% | -3.42% | -8.33% |
| 6 Months | -14.32% | +1.24% | -15.56% |
| 1 Year | -29.23% | -12.55% | -16.69% |
| 2 Year | -38.38% | -0.87% | -37.51% |
| 3 Year | -36.76% | +59.66% | -96.43% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Weakness is detected in governance. This suggests a building risk profile. Risk is increasing at a faster pace.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 9 → 34 over 12 quarters.
- Operating profit margins
Risk Drivers (Active Warnings)
Primary Driver & Insights
Governance Integrity Shock is currently the primary contributor to forensic pressure. Ongoing monitoring of cash generation and balance sheet quality is warranted in upcoming quarters.
Active Risk Objects (3)Free Preview (2 of 3)
EXPLEOSOL: Key governance event detected: DIRECTOR_RESIGNATION.
Governance risk is elevated. Monitor board actions and promoter alignment.
Revenue growth consistently lags behind sector median (16.1%).
Early signs of earnings quality decay. Profitability is being driven by non-core items.
Unlock All 3 Forensic Signals (1 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 3 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Expleo Solutions.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Expleo Solutions.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk deteriorated materially (+18.0 pts), driven by new Relative Growth Weakness (+10.6 pts) and Governance Integrity Shock (+3.2 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated materially (+18.0 pts), driven by new Relative Growth Weakness (+10.6 pts) and Governance Integrity Shock (+3.2 pts).
Business Resilience & Benchmark Context
Overall: HEALTHYPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Watch
Watch
Moderate Deterioration
Moderate Deterioration
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Expleo Solutions.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·10 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Trade Receivables(₹ Cr) | 230 | 222 | 249 | 239 | — | — | — | — | — | — |
Inventories(₹ Cr) | 0 | 0 | 0 | 0 | — | — | — | — | — | — |
Trade Payables(₹ Cr) | 57 | 61 | 28 | 64 | — | — | — | — | — | — |
Net Working Capital(₹ Cr) | 172 | 161 | 222 | 176 | — | — | — | — | — | — |
Working Capital / Sales(%) | 15.0% | 15.5% | 22.8% | 19.1% | — | — | — | — | — | — |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 55d | 57d | 84d | 70d | — | — | — | — | — | — |
Debtor Days (DSO)(days) | 73d | 78d | 94d | 95d | — | — | — | — | — | — |
Inventory Days (DIO)(days) | 0d | 0d | 0d | 0d | — | — | — | — | — | — |
Creditor Days (DPO)(days) | 18d | 21d | 10d | 25d | — | — | — | — | — | — |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | -6.8% | -17.9% | -1.6% | — | — | — | — | — | — | — |
Inventory Growth vs Sales (Δ)(%) | — | — | — | — | — | — | — | — | — | — |
Asset Growth vs Sales (Δ)(%) | +1.7% | +1.6% | -1.0% | — | — | — | — | — | +7.5% | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | 5 | -76 | 19 | 111 | 16 | — | — | — | 7 | -18 |
Accrual Ratio (Accruals / Avg Assets)(%) | 0.5% | -9.6% | 2.5% | 15.2% | — | — | — | — | 3.9% | -10.5% |
Operating Cash Realisation (CFO / EBITDA)(%) | 67.4% | 128.9% | 59.7% | 12.4% | 52.4% | — | — | — | 62.5% | 102.4% |
Capitalisation Intensity (CWIP / Assets)(%) | — | — | — | — | — | — | — | — | — | — |
Concall & Management Takeaways
Q2-FY27Q2-FY27 Results Published • Concall Ingestion Active
Flagium AI is monitoring regulatory exchange filings (NSE/BSE) for EXPLEOSOL's official conference call transcript. Executive themes and management tone will automatically appear once filed.
Business quality remains stable.
Current forensic pressure is elevated and stable.
Key risks remain concentrated in growth sustainability and operating leverage.
The risk profile is Watch and currently deteriorating. Recent structural triggers in governance suggest a building pressure on the underlying framework. Material forensic traces are visible in structural transparency and audit trails, indicating a progressive erosion of structural stability. Strategic vigilance is advised as structural decay is accelerating.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹773, the market expects this company to grow its net profits by -4.8% every year for the next 5 years. If you think the company will grow faster than -4.8%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market currently expects future growth below the company's historical delivery record. Expectations appear conservative relative to the business's track record, resulting in lower expectation risk.
Using the Discounted Cash Flow (DCF) model, the market is pricing EXPLEOSOL for -4.8% long-term growth versus 10.5% historical delivery. Current expectations appear achievable, and historical fundamentals provide strong support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides robust support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | -4.8% | 10.5% | Achievable |
| Operating Margin (EBIT) | 15.8% | 13.7% | Demanding |
| Free Cash Flow Conversion | 62.0% | 78.0% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance below the company's historical record. Historical operating performance currently provides partial evidence that these expectations are sustainable. Continued stronger profitability would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 3 distribution phase. Institutional participation has also deteriorated, compounding the weakening trend as momentum is beginning to decay. Current price action does not yet confirm a decisive breakdown or a renewed advance.
What Is Driving Market Structure?
Market structure shows partial alignment with the underlying fundamental risk profile.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & A/D Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on EXPLEOSOL & 3 market anomalies weekly